- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05853458
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors (HU-F-AIM)
HU-F-AIM - A Prospective, Interventional Study to Evaluate HU-resistance in Polycythemia Vera Patients Who Meet Predictive Parameters Identified in the Machine Learning Project PV-AIM
Study Overview
Detailed Description
This is an open-label, prospective, single arm, Phase IV interventional study to evaluate the HU-resistance/intolerance in PV patients who meet predictive parameters identified in the machine learning project PV-AIM.
The study consists of three periods: screening period, treatment period (observation for HU-resistance/intolerance) and follow-up (FU) period. Eligible participants will enter the treatment period (observation for HU-resistance/intolerance) and start receiving the de novo HU treatment. The maximum treatment duration for each participant in the study will be up to 15 months.
This study will be conducted in a total of 300 adult PV patients and approximately at 30 sites in Germany.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Study Locations
-
-
-
Augsburg, Germany, 86150
- Recruiting
- Novartis Investigative Site
-
Berlin, Germany, 10407
- Recruiting
- Novartis Investigative Site
-
Bonn, Germany, 53113
- Recruiting
- Novartis Investigative Site
-
Donauwoerth, Germany, 86609
- Recruiting
- Novartis Investigative Site
-
Dresden, Germany, 01307
- Recruiting
- Novartis Investigative Site
-
Erding, Germany, 85435
- Recruiting
- Novartis Investigative Site
-
Erfurt, Germany, 99085
- Recruiting
- Novartis Investigative Site
-
Halle, Germany, 06110
- Recruiting
- Novartis Investigative Site
-
Hannover, Germany, 30161
- Recruiting
- Novartis Investigative Site
-
Kiel, Germany, 24105
- Recruiting
- Novartis Investigative Site
-
Koeln, Germany, 50671
- Recruiting
- Novartis Investigative Site
-
Kronach, Germany, 96317
- Recruiting
- Novartis Investigative Site
-
Köln, Germany, 50674
- Recruiting
- Novartis Investigative Site
-
Merseburg, Germany, 06217
- Recruiting
- Novartis Investigative Site
-
Mutlangen, Germany, 73557
- Recruiting
- Novartis Investigative Site
-
Naunhof, Germany, 04683
- Recruiting
- Novartis Investigative Site
-
Offenburg, Germany, 77654
- Recruiting
- Novartis Investigative Site
-
Torgau, Germany, 04860
- Recruiting
- Novartis Investigative Site
-
Westerstede, Germany, 26655
- Recruiting
- Novartis Investigative Site
-
Wuerselen, Germany, 52146
- Recruiting
- Novartis Investigative Site
-
-
Baden-Wuerttemberg
-
Heidelberg, Baden-Wuerttemberg, Germany, 69115
- Recruiting
- Novartis Investigative Site
-
-
Bayern
-
Straubing, Bayern, Germany, 94315
- Recruiting
- Novartis Investigative Site
-
-
Hessen
-
Langen, Hessen, Germany, 63225
- Recruiting
- Novartis Investigative Site
-
-
Niedersachsen
-
Lingen, Niedersachsen, Germany, 49808
- Recruiting
- Novartis Investigative Site
-
-
Nordrhein-Westfalen
-
Dortmund, Nordrhein-Westfalen, Germany, 44309
- Recruiting
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Velbert, North Rhine-Westphalia, Germany, 42551
- Recruiting
- Novartis Investigative Site
-
-
Schleswig-Holstein
-
Luebeck, Schleswig-Holstein, Germany, 23563
- Recruiting
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study
- Confirmed diagnosis of Polycythemia vera (according to WHO 2008, 2016, or 2022 criteria)
- Eastern Cooperative Oncology Group (ECOG) ≤ 2
- No previous pharmacologic cytoreductive therapy (including investigational drugs)
- No phlebotomy in last 28 days
HU-eligible
- High-risk: age ≥ 60 years and/or prior history of thrombosis
Low-risk: showing at least one of the defined criteria
- Signs of disease progression (myeloproliferation)
- Increasing risk of thromboembolism and bleeding:
- Female participants of childbearing potential should have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study treatment.
Exclusion Criteria:
- Patients with post- polycythemia vera myelofibrosis (post-PV MF) or accelerated phase/ blast phase myeloproliferative neoplasm acute myeloid leukemia (AP/BP-MPN AML)
- Patients with a contraindication to HU according to the SmPC (severe bone marrow depression, leukopenia (< 2.5 x 109 leukocytes/l), thrombocytopenia (< 100 x 109 platelets/L), severe anemia (< 10 g/dL HGB)
- Patients with rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption in their past medical history
- Active uncontrolled infection that is considered by the Investigator as a reason for exclusion
- Active malignancies (except for skin cancer; prostate cancer and breast cancer in remission and - where necessary - ongoing hormonal therapy)
- Inadequate liver function as assessed by Investigator
- Inadequate renal function as demonstrated by Modification of Diet in Renal Disease estimate glomerular filtration rate (MDRDeGFR) < 30 mL/min/1.73m2 or on dialysis
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin (hCG) laboratory test.
- Sexually active males unwilling to use a condom during intercourse while taking study treatment and for at least 6 months after stopping study treatment.
- HIV patients treated with nucleoside reverse transcriptase inhibitors like didanosine and stavudine
Other inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hydroxyurea (HU)
Participants will be treated with HU capsules, orally taken, for a maximum duration of 15 months.
|
Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of PV patients with HU-resistance/intolerance within 6-9 months after start of de novo HU- treatment in presence of the PV-AIM HU-resistance predictors at the start of HU treatment.
Time Frame: From 6 to 9 months after start of de novo HU-treatment
|
Proportion of PV participants with HU resistance/intolerance within 6-9 months after start of de novo HU treatment in presence of the PV-AIM HU resistance predictors at the start of HU treatment.
The proportion will be assessed calculating the rate together with the respective 95% confidence interval (CI).
|
From 6 to 9 months after start of de novo HU-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of PV patients who meet the PV-AIM HU-resistance predictors before start of HU-treatment
Time Frame: Baseline
|
Proportion of PV patients who meet the PV-AIM HU-resistance predictors before start of HU-treatment.
The proportion will be assessed calculating the rate together with the respective 95% confidence interval (CI).
|
Baseline
|
Proportion of patients developing HU resistance/intolerance at any time within the maximum treatment period of 15 months
Time Frame: Up to 15 months
|
Proportion of patients developing HU resistance/intolerance at any time within the maximum treatment period of 15 months.
The proportion will be assessed calculating the rate together with the respective 95% confidence interval (CI).
|
Up to 15 months
|
Proportion of "non-switchers"
Time Frame: Up to 15 months
|
For all patients who develop HU resistance/intolerance according to modified European LeukemiaNet (ELN) criteria at any time during the maximum treatment period of 15 months, the proportion of "non-switchers" (i.e., patients remaining on HU despite they meet the HU-resistance/intolerance criteria) will be assessed.
The rate will be calculated together with the respective 95% confidence interval (CI).
|
Up to 15 months
|
Timepoint of therapy switch (after confirmation of HU resistance/intolerance)
Time Frame: Up to 15 months
|
For all patients who develop HU resistance/intolerance according to modified ELN criteria at any time during the maximum treatment period of 15 months, the timepoint of therapy switch (after confimration of HU resistance/intolerance) will be assessed.
|
Up to 15 months
|
Reasons for therapy switch / non-switch
Time Frame: Up to 15 months
|
For all patients who develop HU resistance/intolerance according to modified ELN criteria at any time during the maximum treatment period of 15 months, the reasons for therapy switch or non-switch will be summarized
|
Up to 15 months
|
Therapies applied during follow-up period
Time Frame: Up to 3 months after treatment discontinuation
|
For all patients who develop HU resistance/intolerance according to modified ELN criteria at any time during the maximum treatment period of 15 months, the therapies applied during the follow-up period will be summarized
|
Up to 3 months after treatment discontinuation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Polycythemia Vera
- Polycythemia
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Antisickling Agents
- Hydroxyurea
Other Study ID Numbers
- CINC424BDE15
- 2022-502338-20-00 (Other Identifier: EU CTIS number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycythemia Vera
-
PharmaEssentia Japan K.K.RecruitingPolycythemia Vera (PV)Japan
-
Novartis PharmaceuticalsCompletedPolycythemia Vera (PV)United States
-
PharmaEssentia Japan K.K.Recruiting
-
PharmaEssentia Japan K.K.CompletedPolycythemia Vera (PV)Japan
-
Memorial Sloan Kettering Cancer CenterEli Lilly and Company; Incyte CorporationRecruitingMyelofibrosis Due to and Following Polycythemia VeraUnited States
-
Ionis Pharmaceuticals, Inc.RecruitingPhlebotomy Dependent Polycythemia VeraUnited States, Canada, Hungary, United Kingdom, Australia, Poland
-
Northwestern UniversityNational Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma SocietyWithdrawnPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis PhaseUnited States
-
Novartis PharmaceuticalsTerminatedPrimary Myelofibrosis | Post-Polycythemia Vera | Post-Essential ThrombocytopeniaUnited States
-
CelgeneRecruitingPrimary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera MyelofibrosisFrance, Belgium, Austria, Spain, Australia, Canada, Japan, United States, Korea, Republic of, Romania, Israel, Italy, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Colombia, Argentina, Chile and more
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post-Polycythemia VeraAustralia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Clinical Trials on Hydroxyurea
-
Shiraz University of Medical SciencesCompletedCombination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermediaβ-Thalassemia IntermediaIran, Islamic Republic of
-
Vanderbilt University Medical CenterAminu Kano Teaching Hospital; Murtala Muhammed Specialist HospitalCompletedStroke | Sickle Cell Disease | Sickle Cell AnemiaNigeria
-
Ain Shams UniversityUnknownThalassemia IntermediaEgypt
-
Vanderbilt University Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS); Aminu Kano... and other collaboratorsCompletedStroke | Sickle Cell DiseaseNigeria
-
ItalfarmacoCompletedPolycythemia VeraItaly
-
St. Jude Children's Research HospitalTerminatedSickle Cell Disease | ThalassemiaUnited States
-
UNICANCERCompletedBrain and Central Nervous System TumorsFrance
-
St. Jude Children's Research HospitalCompleted
-
St. Jude Children's Research HospitalCompletedAnemia, Sickle CellUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Anemia, Sickle Cell | Hemoglobinopathies